A US Food and Drug Administration advisory committee has declined to recommend approval of Bristol-Myers Squibb's antiviral drug Bravavir (sorivudine), on the grounds that although the drug was effective, the potentially fatal drug interactions, which caused sorivudine to be pulled off the market in Japan (Marketletters passim), were a worry.
B-MS was trying to get approval of sorivudine for shingles in immunocompromized patients. The panel decided that although the drug offered efficacy which was "at least" equivalent to Glaxo Wellcome's Zovirax (aciclovir) in this indication) as well offering as the convenience of once-daily dosing, to approve the drug for this non-life-threatening indication was not supportable, particularly as the efficacy is comparable to available therapy.
However, the panel did suggest that there may be specific populations of individuals with life-threatening illnesses who might benefit from the drug. For example, it was suggested that it may be used in immunocompromized patients with retinitis. B-MS has studies of sorivudine ongoing in cancer and transplant patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze